Screener
Apogee Therapeutics, Inc. APGE Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:20 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215698
| Line item | THREE MONTHS ENDED MARCH 31, 2026 | THREE MONTHS ENDED MARCH 31, 2025 |
|---|---|---|
| Proceeds from issuance of common stock under the ATM Facility, net of issuance costs | 28,934 | — |
| Proceeds from exercise of options | 4,064 | 622 |
| Net cash provided by financing activities | 411,167 | 622 |
| Increase (decrease) in cash, cash equivalents and restricted cash | 320,248 | (34,873) |
| Cash, cash equivalents and restricted cash, beginning of period | 131,549 | 142,083 |
| Cash, cash equivalents and restricted cash, end of period | $451,797 | $107,210 |
| Supplemental disclosures of non-cash activities: | ||
| Operating lease right-of-use asset obtained in exchange for operating lease liability | — | $999 |
Item 6. [Exhibits](#item_6_exhibits) [71](#item_6_exhibits)
FAQ
- What is Apogee Therapeutics, Inc.'s net change in cash?
- Apogee Therapeutics, Inc. (APGE) reported net change in cash of $320.25M in Q1 2026.
- How has Apogee Therapeutics, Inc.'s net change in cash changed year-over-year?
- Apogee Therapeutics, Inc.'s net change in cash increased by 1018.3% year-over-year, from -$34.87M to $320.25M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Apogee Therapeutics, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude